TY - JOUR
T1 - In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes
AU - Sun, Qiu N.
AU - Fothergill, Annette W.
AU - McCarthy, Dora I.
AU - Rinaldi, Michael G.
AU - Graybill, John R.
PY - 2002
Y1 - 2002
N2 - In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.
AB - In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 μg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.
UR - http://www.scopus.com/inward/record.url?scp=0036233027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036233027&partnerID=8YFLogxK
U2 - 10.1128/AAC.46.5.1581-1582.2002
DO - 10.1128/AAC.46.5.1581-1582.2002
M3 - Article
C2 - 11959605
AN - SCOPUS:0036233027
VL - 46
SP - 1581
EP - 1582
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 5
ER -